Postby Atoq » Sun Nov 26, 2017 10:29 am
Hi! From what I read they talk about ”restaging” after neoadjuvant therapy, meaning that you evaluate the size and regression of the tumor and then it can affect the type of surgery you get and if the sphincter can be saved. But the original stage is the one used in research to pool samples together and see the effects of treatment on survival. The new stage can also push you towards a “sit and wait” strategy, if you have total regression. So both stages are kept, the old and the new one, having different meanings.
I copy a link to a paper about restaging:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3785617/Claudia
1972, 2 kids
Dx rectal cancer 10.2017
T3N2aMX (met left lung 8 mm)
Lynch neg
CEA 1.8
Neoadjuvant chemoradio Xeloda + 25x2 Gy
05.12.17 laparotomic surg. for blockage, colostomy
25.01.18 laparotomic lar, hysterectomy, ileostomy
05.03.18 core needle lung biopsy
07.05.18 CAT scan, lung met 11 mm
04.06.18 ileo reversal
26.06.18 wedge VATS
24.08.18, 31.02.19 CAT scan
12.09.18, 06.02.19 scope, CEA 1.6
19.11.18 scope
20.08.19 CAT, eco
13.09.19 scope, CEA 1.2
18.03.20 CAT, eco, scope, NED
29.11.20 CAT, NED
2023 NED